Available now for replay, PDC*line Pharma 's CEO Eric Halioua presentation at the ARM's Meeting Cell & Gene Meeting on the Mediterranean 2019 (Barcelona). Learn more about the unique mechanism of action of our PDC*line & the clinical developments
Founded in April 2014 in Grenoble (France) as a spin-off of the French Blood Bank (Etablissement Français du Sang, EFS), PDC*line Pharma is a Belgian-French biotech company that is developing a novel class of off-the-shelf cancer immunotherapies based on a proprietary Plasmacytoid Dendritic Cell line (PDC*line) pre-loaded with peptides that are derived from target tumor antigens. Based on a robust preclinical package and a first-in-human phase Ib feasibility study in melanoma, PDC*line Pharma is focusing on lung cancer with a new candidate in early clinical development (PDC*lung) and neoantigens (PDC*Neo). PDC*line Pharma comprises a team of highly skilled professionals based in Liège (Belgium) and Grenoble (France).